Menu

Following FDA OK, 23andMe to Expand Health Prediction

The personal genomics firm is ramping up its suite of disease-related genetic tests.

Oct 21, 2015
Kerry Grens

FLICKR, LEON BROCARDAfter putting a stop in 2013 to 23andMe offering health prediction tests to its consumers, the US Food and Drug Administration (FDA) in February gave the OK for the personal genomics firm to test for one genetic disease. Today (October 21), the company announced it will add 36 additional genetic tests to its health-prediction roster based on expanded FDA approval. The new service will cost $199.

“This isn’t going to get them too far, but maybe it’s a step along the path for them to get rebooted to where they were,” Eric Topol, a genomics professor at the Scripps Research Institute in La Jolla, California, who isn’t affiliated with the company, told The Wall Street Journal.

Nearly two years ago, 23andMe was asked to cease its health and disease tests over concerns about their accuracy. Since then it has only provided ancestry information. In February, the FDA gave the green light to test whether customers are a carrier for Bloom Syndrome. The company’s latest offerings include carrier tests for cystic fibrosis and sickle cell anemia.

“Part of what we tried to do over the last two years is take advantage of being off the market to redesign the entire experience,” Anne Wojcicki, cofounder and chief executive of 23andMe, told The New York Times.

“While FDA has approved carrier tests there still isn’t infrastructure to support the consumption of that information by consumers, and that’s where I have concerns,” Dietrich Stephan, a geneticist at the University of Pittsburgh Medical Center, said in a statement. “The other main point for consumers to be aware of is the issue of awareness and informed consent. Their genetic data and their self-reported survey data are being pushed to internal pharmaceutical development, and may be shared with external pharmaceutical partners outside of 23andMe. It’s legal and above board, but important for consumers to be aware of.”  

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Download this application note from ACEA Biosciences, Inc., to find out how to perform an immunophenotypic analysis of a human blood sample utilizing 13 fluorescent markers using a compact benchtop flow cytometer equipped with 3 lasers!